Autres langues Evelo Biosciences, Inc.

Actions

EVLO

US2997342025

Marché Fermé - OTC Markets Autres places de cotation 19:05:39 29/04/2024			Varia. 5j.	Varia. 1 janv.
0,0419 ^USD	-15,35%		-3,90%	-31,87%

2023	Evelo Biosciences, Inc. annonce la cessation des fonctions de Simba Gill en tant que Chief Executive Officer	CI
2023	Evelo Biosciences, Inc. annonce des changements au sein de sa direction, avec effet au 1er décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

North American Morning Briefing : More Tech -2-	25/04
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04
North American Morning Briefing : Focus Turns to -2-	04/04
North American Morning Briefing : Stocks Set for -2-	28/03
North American Morning Briefing : Investors -2-	21/03
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	14/12
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	11/12
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	11/12
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	21/11
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	21/11
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	21/11
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Sector Update: Health Care Stocks Retreat in Late Afternoon	17/10/23
Sector Update: Health Care	17/10/23
Top Midday Decliners	17/10/23
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	17/10/23
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	17/10/23
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17/10/23
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17/10/23
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	10/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Evelo Biosciences, Inc.

Actions

EVLO

US2997342025

Autres langues

Filtres